Cargando…

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX(®)) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials

Background. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) (nabiximols or Sativex(®)) is an oromucosal spray formulation containing THC and CBD at an approximately 1:1 fixed ratio. Its administration for the treatment of pain in patients with multiple sclerosis (MS) has been established. MS pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turri, Mara, Teatini, Francesco, Donato, Francesco, Zanette, Giampietro, Tugnoli, Valeria, Deotto, Luciano, Bonetti, Bruno, Squintani, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163235/ https://www.ncbi.nlm.nih.gov/pubmed/29933552 http://dx.doi.org/10.3390/medicines5030059

Ejemplares similares

Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
por: D’hooghe, Marie, et al.
Publicado: (2021)

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
por: Patti, F, et al.
Publicado: (2016)

An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex(®) (THC:CBD, nabiximols) oromucosal spray
por: Etges, Tilden, et al.
Publicado: (2016)

A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
por: Twelves, Chris, et al.
Publicado: (2021)

Pharmacokinetics of Sativex(®) in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
por: Fernández-Trapero, María, et al.
Publicado: (2020)

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis‐related spasticity
por: Celius, Elisabeth G., et al.
Publicado: (2018)

A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
por: Überall, Michael A
Publicado: (2020)

Variability of Multiple Sclerosis Spasticity Symptoms in Response to THC:CBD Oromucosal Spray: Tracking Cases through Clinical Scales and Video Recordings
por: Flachenecker, Peter, et al.
Publicado: (2018)

Oromucosal Administration of Interferon to Humans
por: Beilharz, Manfred W., et al.
Publicado: (2010)

The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray)
por: Grimaldi, Alessandro Enrico, et al.
Publicado: (2019)

Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
por: Oppe, Mark, et al.
Publicado: (2021)

Sativex-induced neurobehavioral effects: causal or concausal? A practical advice!
por: Russo, Margherita, et al.
Publicado: (2015)

Sativex in the Management of Multiple Sclerosis-Related Spasticity: Role of the Corticospinal Modulation
por: Russo, Margherita, et al.
Publicado: (2015)

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity
por: Marinelli, Lucio, et al.
Publicado: (2017)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis: Rationale, study design, and methodology
por: Russo, Margherita, et al.
Publicado: (2017)

Oromucosal Alginate Films with Zein Nanoparticles as a Novel Delivery System for Digoxin
por: Rodrigues, Daniela A., et al.
Publicado: (2021)

Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
por: Messina, Silvia, et al.
Publicado: (2017)

Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS‐CoV‐2 infection
por: Rodríguez‐Argente, Francisco, et al.
Publicado: (2020)

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers
por: Stott, Colin, et al.
Publicado: (2013)

Psychosocial Characteristics of Oromucosal Diseases in Psychiatric Patients: Observational Study from Indian Dental College
por: Suresh, K V, et al.
Publicado: (2014)

Use of Detomidine Oromucosal Gel for Alleviation of Acute Anxiety and Fear in Horses: A Pilot Study
por: Dai, Francesca, et al.
Publicado: (2020)

Prevalence of oromucosal lesions in HIV positive patients receiving haart-A prospective clinical study
por: Maloth, Saritha, et al.
Publicado: (2020)

Comparative evaluation of rapidity of action of benzydamine hydrochloride 0.3% oromucosal spray and benzydamine hydrochloride 3 mg lozenges in patients with acute sore throat: A phase IV randomized trial
por: Valerio, Carmelina, et al.
Publicado: (2023)

Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach
por: Wright, Stephen, et al.
Publicado: (2012)

Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
por: Valdeolivas, Sara, et al.
Publicado: (2017)

Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2019)

Oral Health Status and Oromucosal Lesions in Patients Living with HIV/AIDS in India: A Comparative Study
por: Kumar, Sandeep, et al.
Publicado: (2014)

Evaluation of Oromucosal Natural Gum-Based Emulgels as Novel Strategy for Photodynamic Therapy of Oral Premalignant Lesions
por: Szymańska, Emilia, et al.
Publicado: (2023)

Scalp‐recorded N40 visual evoked potential: Sensory and attentional properties
por: Proverbio, Alice Mado, et al.
Publicado: (2021)

Advances in the Prophylaxis of Respiratory Infections by the Nasal and the Oromucosal Route: Relevance to the Fight with the SARS-CoV-2 Pandemic
por: Ivanova, Nadezhda, et al.
Publicado: (2022)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

Sensory Attenuation Assessed by Sensory Evoked Potentials in Functional Movement Disorders
por: Macerollo, Antonella, et al.
Publicado: (2015)

State-dependence of sensory-evoked responses in neocortex
por: Curto, Carina, et al.
Publicado: (2007)

Feasibility of cerebello-cortical stimulation for intraoperative neurophysiological monitoring of cerebellar mutism
por: Giampiccolo, Davide, et al.
Publicado: (2021)

Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2021)

Very early and early neurophysiological abnormalities in Guillain–Barré syndrome: A 4‐year retrospective study
por: Rasera, Andrea, et al.
Publicado: (2021)

Evaluation of repeated dosing of a dexmedetomidine oromucosal gel for treatment of noise aversion in dogs over a series of noise events
por: Gruen, Margaret, et al.
Publicado: (2020)

Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor
por: Selvarajah, Dinesh, et al.
Publicado: (2010)

Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis
por: Hilliard, A., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_99sd8b0duc8vcgom3rji55t4sv